Work

High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma

Year: 2026

Type: article

Study design: Clinical Trial

Source: Melanoma Research

DOI: 10.1097/cmr.0000000000001102

Authors: Tali Azenkot, Mina Nikanjam, Soham Mhatre, Jaren T. Mullen, Donald A. Barkauskas, Rana R. McKay, Joel M. Baumgartner, Gregory A. Daniels

Institutions: University of California San Diego, Moores Cancer Center, University of Miami, University of Southern California

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7160145483

FWCI:

Cites: 35

Cited by:

Related to: